President and Chief Technology Officer Transitions to Advisory Role
Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence (“AI”) health diagnostic solutions, today announced that the Company’s President and Chief Technology Officer, Mr. Anthony Schaller, has transitioned from the Company’s President and Chief Technology Officer to an advisory role.
Mr. Schaller has been instrumental in leading the Company’s product development initiatives since late 2024 culminating with the Company’s first version of its commercially oriented software completion. The Company is now transitioning to focus on its regulatory and commercialization initiatives.
“I would like to acknowledge and thank Anthony for his efforts to Light AI over the past year,” stated Mr. Peter Whitehead, Chief Executive Officer of Light AI. “The Company is leveraging its extensive research and related product development investment as it transitions to the regulatory process and commercialization initiatives phase to capitalize on its large market opportunity. I look forward to Anthony continuing to support as an advisor going forward.”
About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF)
Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images–starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions –to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind–its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.
In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI’s vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.
Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth
Source: Light AI Inc.
